25 juni 2012: In Azië komt veel meer primaire leverkanker voor dan in Europa en Amerika. En daar ook wordt meer onderzoek gedaan naar minder belastende behandelingen voor levertumoren. Zoals onderstaande studies naar het gebruik van curcuma olie samen met bepaalde Chinese kruiden bij TACE - Trans Arteriële Chemo Embolisatie. Onderaan hebben we 2 studies toegevoegd met vergelijkbare resultaten op levensduur en ziektevrije tijd met curcuma olie plus Chinese kruiden in vergelijking met chemo. De bijwerkingen met curcuma olie waren veel minder met curcuma olie dan met chemo. Zie abstract van de 2 studies onderaan dit artikel.

13 juni 2011:

Veel mensen vergeten dat TACE - Trans Arteriele Chemo Embolisatie een behandeling is die wel levensverlenging geeft maar zelden overall overleving. Toch kunnen andere middelen die levensduur significant verlengen. Zie o.a. onderstaande studie naar effect van curcuma olie i.p.v. chemo bij TACE.

13 augustus 2005: bron: Zhongguo Zhong Xi Yi Jie He Za Zhi. 2001 Mar;21(3):165-7.

Chinese onderzoekers deden onderzoek naar de effecten van curcuma olie in vergelijking met chemo bij HAI = Arteriële toediening en TACE = Trans Arteriële toediening bij primaire leverkanker. De resultaten zijn goed. In vergelijking met HAI was het therapeutische effect gelijk, bij TACE was het effect van gebruik van curcuma olie zelfs beduidend beter op mediane overleving en ziektevrije tijd dan bij chemo gebruik. De kwaliteit van leven en de bijwerkingen waren bij het gebruik van curcuma olie ook beduidend beter dan bij gebruik van chemo. Een zeer interessante studie o.i.

[A controlled clinical study between hepatic arterial infusion with embolized curcuma aromatic oil and chemical drugs in treating primary liver cancer]

[Article in Chinese]

Cheng JH, Chang G, Wu WY.

Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou 510120.

OBJECTIVE: To evaluate the effectiveness, toxicity and prospective application of hepatic arterial infusion (HAI) with Embolized Curcuma Aromatic oil (CAO) in treating primary liver cancer (PLC).

METHODS: In the treated group, 32 patients with PLC were treated by HAI with 1-3 ml of embolized CAO and oral administration of Chinese herbal medicine. In the control group, 32 patients with PLC were treated with transcatheter artery chemoembolization (TACE).

RESULTS: In the treated group, one patient attained complete remission (CR) and 13 partial remission (PR), the total effective rate being 43.75%. The level of alpha fetal protein (AFP) turned to normal range in 7 cases and decreased in other 7. In the control group, 10 obtained PR and the total effective rate being 31.25%, AFP level turned to normal in 5 and decreased in 2. There was no statistical significance between the two groups. The incidences of post-embolism syndrome, such as fever, abdominal pain and vomiting were similar between the two groups but no myelosuppression occurred in the treated group with significant difference (P < 0.01) as comparing with that in the control group. The mean survival time, median survival time, 1-, 2- and 3-year survival rate in the treated group was 11.5 months, 10 months, 37.5%, 13.3% and 6.9% respectively, while in the control group was 7.25 months, 6 months, 15.6%, 3.2% and 0 respectively. The treated group was better in mean survival time, median survival time and 1-year survival rate than that of the control group (P < 0.05).

CONCLUSION: HAI with embolized CAO showed a similar favorite effect in treating PLC as that of TACE, but superior than TACE with longer survival time and milder myelosuppression. PMID: 12577327 [PubMed - indexed for MEDLINE]

Chinese anti-cancer medicinal perfusion/embolization has affirmative short-term clinical effect in treating primary liver cancer with few adverse reactions, which was tolerable to patients

Zhongguo Zhong Xi Yi Jie He Za Zhi. 2005 Apr;25(4):299-302.

[Clinical study on comprehensive treatment of primary liver cancer mainly with chinese medicinal perfusion/embolization].

[Article in Chinese]

Xu K, Luo HY, Li LN.

Source

Second Clinical Medical College, Guangzhou University of TCM, Guangzhou. xukaiguangzhou@263.net

Abstract

OBJECTIVE:

To study the clinical efficacy and adverse reaction of comprehensive therapy mainly with Chinese anti-cancer medicinal perfusion/embolization and assisted with Chinese drug-therapy based on TCM Syndrome Differentiation in treating primary liver cancer.

METHODS:

Forty-one patients with liver cancer were divided into the treated group and the control group. To the treated group turmeric oil microballoon, cinobufotalin, Aidi injection and iodized oil were given via hepatic artery perfusion/embolization, and to the control group chemotherapeutic agents and iodized oil were given for instead. Besides, both groups were given Chinese herbs according to TCM Syndrome Differentiation additionally.

RESULTS:

The tumor inhibitory rate in the treated group and the control group was 77.78% and 69.57% respectively, with insignificant difference between them. The improvement of fatigue and anorexia in the treated group was better than that in the control group (P < 0. 05). The 6-month, 12-month and 24-month survival rate in the treated group and control group was 61.11% vs 56.62%, 27.78% vs 30.43% and 22.22% vs 26.09%, respectively, the difference between the two groups was insignificant. The occurrence of adverse reactions such as decreasing of white blood cells, platelet and hemoglobin, nausea and vomiting were obviously lower in the treated group than those in the control group (P < 0.05).

CONCLUSION:

Chinese anti-cancer medicinal perfusion/embolization has affirmative short-term clinical effect in treating primary liver cancer with few adverse reactions, which was tolerable to patients, but its long-term clinical efficacy needs further observation.

PMID:: 15892270; [PubMed - indexed for MEDLINE]

Chinese medicine comprehensive therapy is an effective treatment for the middle/late stage patients of primary liver cancer - PHC - , and it could extend the PRST, improve the patients' quality of life and long-term survival with less adverse reaction.

Chin J Integr Med. 2010 Apr;16(2):102-8. Epub 2010 May 16.

Treatment of middle/late stage primary hepatic carcinoma by Chinese medicine comprehensive therapy: A prospective randomized controlled study.

Tian HQ, Li HL, Wang B, Liang GW, Huang XQ, Huang ZQ, Lang JM, Zhang YP, Chen XZ, Chen YS.

Source

Department of Oncology, Foshan Municipal Hospital of Traditional Chinese Medicine, Guangdong (528000), China. wangbin_19792003@yahoo.com.cn

Abstract

OBJECTIVE:

To observe the efficacy of Chinese medicine comprehensive therapeutic project in treating the middle/late stage primary hepatic carcinoma (PHC).

METHODS:

With prospective randomized controlled design, 97 patients with PHC were assigned to the test group (49 cases) treated with Chinese medicine comprehensive therapy using Oleum fructus bruceas intervention combining oral intake of Ganji Decoction and external application of Ailitong, and the control group (48 cases) treated with chemotherapeutic agents combining iodized oil chemo-embolization and analgesics. The immediate and long-term efficacy, adverse reaction, pain-relieving initial time (PRIT) and pain-relieving sustained time (PRST) of the treatment, as well as the change in relieving patients' quality of life (QOL) were observed.

RESULTS:

The difference between the two groups in illness control rate was statistically insignificant (P>0.05), but the adverse reaction occurrence rate in the test group was lesser than that in the control group (P<0.05). PRIT was insignificantly different in the two groups (P>0.05), but the PRST was significantly superior in the test group than that in the control group (10.37+/-2.18 h vs 7.78+/-1.95 h, P<0.01). After treatment, the increased Karnofsky scores in the test group indicated that the patients' somatic activity, symptoms and QOL were improved significantly, which were significantly superior to those in the control group (P<0.05). The survival rate in the two groups was similar at the 3rd month after treatment, but the test group did show superiority in terms of half- and 1-year survival rate (65.9% vs 42.5% and 38.6% vs 18.1%, respectively, P<0.05). The median survival time in the test group was 8.9 months and that in the control group was 5.3 months.

CONCLUSION:

Chinese medicine comprehensive therapy is an effective treatment for the middle/late stage patients of PHC, and it could extend the PRST, improve the patients' QOL and long-term survival with less adverse reaction.